Trial Profile

A phase II randomized, observer-blind, active-controlled study to evaluate the immunogenicity and safety of a single dose of BioNet-Asiaâ??s acellular pertussis-only vaccine and its combined tetanus-diphtheria-acellular pertussis vaccine at multiple

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Diphtheria tetanus acellular pertussis vaccine-Bionet-Asia (Primary) ; DTaP vaccine (Primary)
Indications Pertussis
Focus Pharmacodynamics
Sponsors BioNet-Asia

06 Dec 2023 Results assessing the efficacy maternal antibody transfer and safety data in mothers and neonates immunization with different doses of recombinant pertussis-containing vaccines, published in the Vaccine.
15 Jun 2023 Results published in the Vaccine
09 Apr 2019 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com